The incidence and risk factors for ovarian metastasis and overall survival with ovarian preservation for early-stage adenocarcinoma of the cervix-A meta-analysis
Dong-jin Wu, Lihua Zhang, Nitish Beharee, Li Yang, Yinan Wu, Yingchun Wang, Mengmeng Lv, Jin Lu, Jinhua Wang
{"title":"The incidence and risk factors for ovarian metastasis and overall survival with ovarian preservation for early-stage adenocarcinoma of the cervix-A meta-analysis","authors":"Dong-jin Wu, Lihua Zhang, Nitish Beharee, Li Yang, Yinan Wu, Yingchun Wang, Mengmeng Lv, Jin Lu, Jinhua Wang","doi":"10.31083/j.ejgo4301006","DOIUrl":null,"url":null,"abstract":"Objective: To compare the incidence of ovarian metastasis (OM) in early stage adenocarcinoma (AC) and squamous cell carcinoma (SCC) of the cervix, evaluate the overall survival with ovarian preservation and determine risk factors of OM for early stage AC. Data sources, methods of study selection: We searched the Cochranes database, Embase, and PubMed for publications to November 2020. The articles reporting the incidence, risk factors and overall survival of OM in AC were included. Articles that lacked sufficient data of the odds ratios (ORs) and 95% confidence intervals (CIs) were excluded. A fixed effects model was used to calculate OR and 95% CIs. Eggers test and Funnel plot were used to test the publication bias. Forest plots was used to present and synthesise results. Tabulation, integration and results: In the meta-analysis, the incidence of OM of AC was higher than that of SCC (OR 5.68, 95% CI 4.40–7.32, I = 28.1%) in stage IA-IIB. The incidence of OM was 0% in stage IA, 2.72% in stage IB, 5.95% in stage IIA, and 12.86% in stage IIB AC. Ovarian preservation was not significantly associated with OS (OR 0.53, 95% CI 0.35–0.80, I = 37.8%) in early stage of AC. We found seven risk factors for OM: deep stromal invasion (OR 8.80, 95% CI 3.20–24.23, I = 0%), corpus uteri invasion (OR 6.29, 95% CI 3.36–11.77, I = 21.8%), tumor size>4 cm (OR 3.78, 95% CI 1.86–7.69, I = 30.5%), FIGO stage IIA (OR 3.67, 95% CI 1.98–6.81, I = 0%), FIGO stage IIB (OR 4.31, 95% CI 2.74–6.77, I = 0%), FIGO stage II (OR 3.99, 95% CI 2.49–6.41, I = 0%) and lympho-vascular space invasion (OR 2.90, 95% CI 1.36–6.17, I = 0%). Conclusions: Ovarian preservation is only recommended in stage IA and stage IB AC without risk factors, but not reasonable for stage IIA and IIB AC. Both stage IIA and IIB are risk factors for OM in early stage AC.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2022-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of gynaecological oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31083/j.ejgo4301006","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To compare the incidence of ovarian metastasis (OM) in early stage adenocarcinoma (AC) and squamous cell carcinoma (SCC) of the cervix, evaluate the overall survival with ovarian preservation and determine risk factors of OM for early stage AC. Data sources, methods of study selection: We searched the Cochranes database, Embase, and PubMed for publications to November 2020. The articles reporting the incidence, risk factors and overall survival of OM in AC were included. Articles that lacked sufficient data of the odds ratios (ORs) and 95% confidence intervals (CIs) were excluded. A fixed effects model was used to calculate OR and 95% CIs. Eggers test and Funnel plot were used to test the publication bias. Forest plots was used to present and synthesise results. Tabulation, integration and results: In the meta-analysis, the incidence of OM of AC was higher than that of SCC (OR 5.68, 95% CI 4.40–7.32, I = 28.1%) in stage IA-IIB. The incidence of OM was 0% in stage IA, 2.72% in stage IB, 5.95% in stage IIA, and 12.86% in stage IIB AC. Ovarian preservation was not significantly associated with OS (OR 0.53, 95% CI 0.35–0.80, I = 37.8%) in early stage of AC. We found seven risk factors for OM: deep stromal invasion (OR 8.80, 95% CI 3.20–24.23, I = 0%), corpus uteri invasion (OR 6.29, 95% CI 3.36–11.77, I = 21.8%), tumor size>4 cm (OR 3.78, 95% CI 1.86–7.69, I = 30.5%), FIGO stage IIA (OR 3.67, 95% CI 1.98–6.81, I = 0%), FIGO stage IIB (OR 4.31, 95% CI 2.74–6.77, I = 0%), FIGO stage II (OR 3.99, 95% CI 2.49–6.41, I = 0%) and lympho-vascular space invasion (OR 2.90, 95% CI 1.36–6.17, I = 0%). Conclusions: Ovarian preservation is only recommended in stage IA and stage IB AC without risk factors, but not reasonable for stage IIA and IIB AC. Both stage IIA and IIB are risk factors for OM in early stage AC.
目的:比较早期宫颈腺癌(AC)和鳞状细胞癌(SCC)卵巢转移(OM)的发生率,评估保留卵巢的总生存率,确定早期AC卵巢转移的危险因素。数据来源、研究选择方法:我们检索Cochranes数据库、Embase和PubMed,检索截至2020年11月的出版物。纳入了报道AC中OM的发病率、危险因素和总生存率的文章。排除了缺乏足够的比值比(ORs)和95%置信区间(ci)数据的文章。采用固定效应模型计算OR和95% ci。采用Eggers检验和Funnel图检验发表偏倚。森林样地用于呈现和综合结果。表列、整合和结果:在meta分析中,在IA-IIB期,AC的OM发生率高于SCC (OR 5.68, 95% CI 4.40-7.32, I = 28.1%)。卵巢癌在IA期的发生率为0%,IB期为2.72%,IIA期为5.95%,IIB期为12.86%。在AC早期,卵巢保留与OS无显著相关性(OR 0.53, 95% CI 0.35-0.80, I = 37.8%)。我们发现卵巢癌的7个危险因素:深间质浸润(OR 8.80, 95% CI 3.20-24.23, I = 0%)、子宫浸润(OR 6.29, 95% CI 3.36-11.77, I = 21.8%)、肿瘤大小bbbb4 cm (OR 3.78, 95% CI 1.86-7.69, I = 30.5%)、FIGO分期IIA (OR 3.67, 95% CI 1.98-6.81, I = 0%)、FIGO分期IIB (OR 4.31, 95% CI 2.74-6.77, I = 0%)、FIGO分期II (OR 3.99, 95% CI 2.49-6.41, I = 0%)和淋巴血管间隙浸润(OR 2.90, 95% CI 1.36-6.17, I = 0%)。结论:卵巢保留仅在无危险因素的IA期和IB期AC中推荐,而在IIA期和IIB期AC中不合理。IIA期和IIB期都是早期AC发生OM的危险因素。
期刊介绍:
EJGO is dedicated to publishing editorial articles in the Distinguished Expert Series and original research papers, case reports, letters to the Editor, book reviews, and newsletters. The Journal was founded in 1980 the second gynaecologic oncology hyperspecialization Journal in the world. Its aim is the diffusion of scientific, clinical and practical progress, and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists, and so on.